Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC to Prevent Anti-TB Drug-induced Liver Injury
NCT05738681Phase 3Unknown
- Sponsor
- Mahidol University
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetylcysteine in drug induced liver injury (DILI) (2 arms), sponsored by Mahidol University. Primary endpoint: Prevalence of hepatitis at 8 weeks. Status: unknown.
02
Drugs
acetylcysteine
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT05738681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738681.